Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Baseline Characteristics of the VANISH Cohort

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Sex-Related Differences in Heart Failure With Preserved Ejection Fraction

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Duration of Heart Failure and Effect of Defibrillator Implantation in Patients With Nonischemic Systolic Heart Failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Alcohol septal ablation in patients with severe septal hypertrophy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Screening relatives in arrhythmogenic right ventricular cardiomyopathy: yield of imaging and electrical investigations

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Anna Axelsson Raja
  • Ling Shi
  • Sharlene M Day
  • Mark Russell
  • Kenneth Zahka
  • Harry Lever
  • Steven D Colan
  • Renee Margossian
  • E Kevin Hall
  • Jason Becker
  • John Lynn Jefferies
  • Amit R Patel
  • Lubna Choudhury
  • Anne M Murphy
  • Charles Canter
  • Richard Bach
  • Matthew Taylor
  • Luisa Mestroni
  • Matthew T Wheeler
  • Lee Benson
  • Anjali T Owens
  • Joseph Rossano
  • Kimberly Y Lin
  • Elfriede Pahl
  • Alexandre C Pereira
  • Henning Bundgaard
  • Gregory D Lewis
  • Jose D Vargas
  • Allison L Cirino
  • John J V McMurray
  • Calum A MacRae
  • Scott D Solomon
  • E John Orav
  • Eugene Braunwald
  • Carolyn Y Ho
Vis graf over relationer

BACKGROUND: The VANISH trial (Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy) targeted young sarcomeric gene mutation carriers with early-stage hypertrophic cardiomyopathy (HCM) to test whether valsartan can modify disease progression. We describe the baseline characteristics of the VANISH cohort and compare to previous trials evaluating angiotensin receptor blockers.

METHODS: Applying a randomized, double-blinded, placebo-controlled design, 178 participants with nonobstructive HCM (age, 23.3±10.1 years; 61% men) were randomized in the primary cohort and 34 (age, 16.5±4.9 years; 50% men) in the exploratory cohort of sarcomeric mutation carriers without left ventricular hypertrophy.

RESULTS: In the primary cohort, maximal left ventricular wall thickness was 17±4 mm for adults and Z score 7.0±4.5 for children. Nineteen percent had late gadolinium enhancement on cardiac magnetic resonance. Mean peak oxygen consumption was 33 mL/kg per minute, and 92% of participants were New York Heart Association functional class I. New York Heart Association class II was associated with older age, MYH7 variants, and more prominent imaging abnormalities. Six previous trials of angiotensin receptor blockers in HCM enrolled a median of 24 patients (range, 19-133) with mean age of 51.2 years; 42% of patients were in New York Heart Association class ≥II, and sarcomeric mutations were not required.

CONCLUSIONS: The VANISH cohort is much larger, younger, less heterogeneous, and has less advanced disease than prior angiotensin receptor blocker trials in HCM. Participants had relatively normal functional capacity and mild HCM features. New York Heart Association functional class II symptoms were associated with older age, more prominent imaging abnormalities, and MYH7 variants, suggesting both phenotype and genotype contribute to disease manifestations.

CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01912534.

OriginalsprogEngelsk
TidsskriftCirculation. Heart failure
Vol/bind12
Udgave nummer12
Sider (fra-til)e006231
ISSN1941-3289
DOI
StatusUdgivet - dec. 2019

ID: 59438236